Zoey Becker is a Staff Writer for Fierce Pharma, a leading publication in the pharmaceutical industry. With a focus on providing timely and insightful coverage, Zoey's articles delve into the latest developments, mergers and acquisitions, legal battles, and regulatory updates in the pharmaceutical and biotech sectors.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Zoey's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly on legal developments, mergers and acquisitions, drug development, and patent disputes. The majority of her articles are driven by press releases and government announcements.
For effective outreach to Zoey Becker, consider providing insights into ongoing legal battles in the pharmaceutical industry or exclusive information related to major mergers and acquisitions within the sector. Additionally, experts with knowledge about regulatory changes impacting drug development or those who can provide analysis based on credible data could be valuable sources for Zoey's reporting.
Given that her coverage attributes include a significant percentage of press releases as sources of information, she might also be interested in receiving embargoed news or early access to upcoming announcements within the healthcare and pharmaceutical space.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Zoey Becker
Robert F. Kennedy Jr.'s appointment last month to lead the U.S. Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry.
By: Zoey Becker
Antag Therapeutics thinks its glucose dependent insulinotropic polypeptide receptor (GIPR) antagonist could carve out a space in the buzzy obesity
By: Zoey Becker
Novartis' latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a federal appeals court.
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.
By: Zoey Becker
Amid ongoing speculation about how the biopharmaceutical sector will fare under Donald Trump's second presidency, the President-elect hosted several
By: Zoey Becker
Gilead Sciences' top money maker Biktarvy has been the company's crown jewel for years now, but with the HIV med inching toward a 2033 patent cliff, the drugmaker at its HIV investor event laid out an analyst-lauded plan to extend its HIV dominance into the next decade and beyond.
It's déjà vu for Siga Technologies and its smallpox antiviral Tpoxx. At an interim analysis of a second mpox trial, the drug again missed the mark on a key measure of disease resolution.
By: Darren Incorvaia, Zoey Becker
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.
By: Zoey Becker
Lexicon Pharmaceuticals has already thrown in the towel on its commercial efforts after a years-long uphill battle to get its insulin adjunct prospect Zynquista (sotagliflozin) across the FDA finish line.
(833) 317-6278 
